



Todd Pope
President & CEO

Cowen and Company 37th Annual Health Care Conference
March 7, 2017



Forward Looking Statements

This presentation includes statements relating to TransEnterix's current regulatory and commercialization plans for our products, the Senhance™ Surgical Robotic System and the SurgiBot™ System. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the commercialization of the Senhance Surgical Robotics System will be successful, whether and when we will prepare a 510(k) submission for the Senhance Surgical Robotic System, the pace of adoption of our products by surgeons, the success and market opportunity of our products, our current cash reach, the effect on our business of existing and new regulatory requirements and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our including our Annual Report on Form 10-K filed on March 6, 2017 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of the presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.





TransEnterix: TRXC

Focus: Surgical Robotics

Compelling Platform Technology


- Senhance Surgical Robot
- Robotic benefits with responsible economics

Significant addressable market opportunity

- Surgical robotics growing but minimally penetrated

Recent highlights


- Announced first sale in Germany Feb, '17
- Surgeon user base and procedure volume growing rapidly
- Launched clinical leadership program – UK, France and Italian sites established





Surgical Robotics Poised for Growth

Abdominal Robotic Surgery Market Size




Procedure expansion, geographic expansion and new entrants will grow abdominal robotic surgery market significantly





Benefits of Surgical Robotics






Robotic Adoption Remains Low

- Traditional laparoscopy remains the dominant form of minimally invasive surgery
- Over 6 million laparoscopic procedures across US and CE Mark countries
- Surgeons are experienced with approach, technique and instrument motion


+ Benefits — Trade-offs = Limited adoption

Accessing the benefits of robotics has required accepting trade-offs that can't always be justified with competing systems





Trade-offs of Competing Systems





Enhance Surgery



Builds on the foundation of laparoscopy: Highly efficient operations with minimal additional docking time or change to technique



Robotic precision: Performing precise, complex surgery in a more minimally invasive manner



Comfortable ergonomics: Increased comfort and reduced strain for the surgeon



The security of haptics: Safe management of the operation by retaining sensing of touch



Eye-sensing camera control: Increases surgeon control over vision and multiple instruments



Advanced technology with responsible economics: Managing operative costs effectively




Senhance – Responsible Economics



Advanced technology with responsible economics: Managing operative costs effectively

- Reusable instruments
- Minimal disposables/case
- Fast set up and instrument exchange
- Leverage existing hospital infrastructure

Access to robotics, but with costs similar to laparoscopy






Open Architecture Leverages the True Hospital Ecosystem



Advanced technology with responsible economics: Managing operative costs effective

- Hospitals make major investments in existing OR beds, endoscope systems, imaging technologies
- Surgeons have developed strong preference for many of these technologies
- Strategy enables interoperability with existing surgical technologies





Commercial Activity

- Strong foundation established
 - Direct sales team covering Germany, France & UK
 - Distributors and agents covering Australia, New Zealand, Taiwan, Kuwait, UAE, Austria, Switzerland, Italy
 - Strong presence at trade shows and leveraging mobile demonstrations
- Sales activities
 - Italian first sale Q3 '16
 - German first sale in Q1 '17
 - Two additional systems placed with option to buy
 - 12-18 month sales cycle
- US FDA clearance expected 2017





Clinical Leadership Program

- Partner with influential institutions and surgeons
 - Establish clinical reference sites
 - Expand utilization across specialties & procedures
 - Generate clinical data
- First Clinical Leadership Site is Imperial College NHS Trust in London, UK
 - System installed on site in Nov 2016
- 2 additional sites established in Q4 '16 – France/Italy
- One additional site planned





Recent Updates

- Appointed Wouter Donders, GM Europe
- Sales to hospitals with and without existing robotics programs
- User base now eight surgeons in 3 countries
- Demonstrating ability to convert laparoscopic procedures to Senhance
 - Fast OR turnaround time
 - Multiple cases in a single day





Key Priorities

- Commercialize Senhance in CE Mark countries
- Partner with leading institutions and surgeons
- Obtain Senhance US 510(k) clearance
- Leverage open architecture to complement existing hospital investments





 TransEnterix®